Literature DB >> 10802870

Primary gastric lymphoma: brief overview of the recent Princess Margaret Hospital experience.

M K Gospodarowicz1, M Pintilie, R Tsang, B Patterson, A Bezjak, W Wells.   

Abstract

Primary gastric lymphoma is the commonest form of presentation for gastrointestinal lymphomas and the stomach is one of the most frequent sites of extranodal lymphoma. We present a review of the Princess Margaret Hospital (PMH) experience to illustrate the favorable prognosis and examine the long-term outcomes in this disease. Between 1967 and 1996, 149 consecutive patients with gastric lymphoma were treated at the PMH. The majority (122 patients) presented with diffuse large-cell lymphoma and 78 had stage I disease. In the past, the standard treatment was surgery (partial gastrectomy) followed by post-operative radiation therapy (RT; 78 patients). The overall 10-year survival was 62%. For patients who were treated with surgery and post-operative RT (operable disease) between 1967 and 1985, the 10-year rates of overall survival and cause-specific survival were 66.2% and 88%, respectively. In the past decade, combined-modality therapy with chemotherapy followed by RT was introduced for large-cell lymphoma, while RT alone was used for mucosa-associated lymphoid tissue (MALT) lymphoma. In 45 patients treated in the past decade, the overall 5-year survival was 86%, the cause-specific survival was 95.5%, and the relapse-free rate was 87.3%. These results support the view that primary gastric lymphoma is a highly curable disease. Future efforts should focus on reducing treatment morbidity, while preserving excellent results.

Entities:  

Mesh:

Year:  2000        PMID: 10802870     DOI: 10.1007/978-3-642-57054-4_14

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  1 in total

Review 1.  The Evolution in the Management of Gastric Lymphoma.

Authors:  Dana Hashim; Mariya Apostolova; Simon Lavotskin; Evan Goldstein; Mitchell Chorost
Journal:  Gastroenterology Res       Date:  2009-09-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.